Literature DB >> 23768780

Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1).

San Zeng1, May P Xiong.   

Abstract

A three layer (trilayer) pan class="Chemical">polymeric micelle system based on the self-association of the triblock polymer poly(ethylene glycol)-b-poly{N-[N-(2-aminoethyl)-2-aminoethyl] aspartamide}-b-poly-caprolactone) (PEG-b-PAsp(DET)-b-PCL) has been synthesized and investigated for combination delivery of rapamycin (RAP) and siRNA targeting Y-box binding protein-1 (siYB-1). The trilayer micelle is composed of (a) a hydrophilic poly(ethylene glycol) (PEG) block constituting the outer layer to improve pharmacokinetics, (b) an intermediate compartment composed of the cationic poly{2-[(2-aminoethyl)amino] ethyl aspartamide} (PAsp(DET)) segment for interacting with siYB-1, and (c) an inner hydrophobic poly-caprolactone) (PCL) compartment for encapsulation of RAP. A major advantage of this system is biocompatibility since PEG and PCL are both approved by the FDA, and PAsp(DET) is a non-toxic pH responsive cationic poly(amino acid)-based polymer. In this study, it has been shown that PCL can encapsulate RAP with high loading efficiencies, and PAsp(DET) can successfully interact with siRNA for efficient transfection/knockdown with negligible cytotoxicity. The enhanced therapeutic efficacy of RAP/siYB-1 micelles was demonstrated in cell cultures and in a PC3 xenograft nude mouse model of human prostate cancer. Herein, we demonstrate that trilayer micelles are a promising approach to improve the simultaneous delivery of combination siRNA/drug therapies.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23768780      PMCID: PMC3816790          DOI: 10.1016/j.biomaterials.2013.05.010

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  58 in total

Review 1.  Lysosomes and autophagy in cell death control.

Authors:  Guido Kroemer; Marja Jäättelä
Journal:  Nat Rev Cancer       Date:  2005-11       Impact factor: 60.716

2.  Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer.

Authors:  Markus Guba; Gudrun E Koehl; Evelyn Neppl; Axel Doenecke; Markus Steinbauer; Hans J Schlitt; Karl-Walter Jauch; Edward K Geissler
Journal:  Transpl Int       Date:  2005-01       Impact factor: 3.782

3.  Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer.

Authors:  Thomas Knösel; Anna Emde; Karsten Schlüns; Yuan Chen; Karsten Jürchott; Matthias Krause; Manfred Dietel; Iver Petersen
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

4.  In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.

Authors:  M Laird Forrest; Chee-Youb Won; A Waseem Malick; Glen S Kwon
Journal:  J Control Release       Date:  2005-11-18       Impact factor: 9.776

5.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.

Authors:  Shiladitya Sengupta; David Eavarone; Ishan Capila; Ganlin Zhao; Nicki Watson; Tanyel Kiziltepe; Ram Sasisekharan
Journal:  Nature       Date:  2005-07-28       Impact factor: 49.962

Review 6.  PI3K/Akt/mTOR pathway as a target for cancer therapy.

Authors:  Daniel Morgensztern; Howard L McLeod
Journal:  Anticancer Drugs       Date:  2005-09       Impact factor: 2.248

Review 7.  Current development of mTOR inhibitors as anticancer agents.

Authors:  Sandrine Faivre; Guido Kroemer; Eric Raymond
Journal:  Nat Rev Drug Discov       Date:  2006-08       Impact factor: 84.694

8.  Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells.

Authors:  Tomonori Sato; Maiko Suzuki; Yoshitaro Sato; Seishi Echigo; Hidemi Rikiishi
Journal:  Int J Oncol       Date:  2006-05       Impact factor: 5.650

9.  Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.

Authors:  James V Alvarez; Heidi Greulich; William R Sellers; Matthew Meyerson; David A Frank
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

Review 10.  Signal transducers and activators of transcription (STATs): Novel targets of chemopreventive and chemotherapeutic drugs.

Authors:  Lidija Klampfer
Journal:  Curr Cancer Drug Targets       Date:  2006-03       Impact factor: 3.428

View more
  8 in total

Review 1.  Nanoparticulate RNA delivery systems in cancer.

Authors:  Ankur Sharma; Niraj Kumar Jha; Kajal Dahiya; Vivek Kumar Singh; Kundan Chaurasiya; Aditya Narayan Jha; Saurabh Kumar Jha; Prabhu Chandra Mishra; Sunny Dholpuria; Rani Astya; Parma Nand; Amit Kumar; Janne Ruokolainen; Kavindra Kumar Kesari
Journal:  Cancer Rep (Hoboken)       Date:  2020-07-30

Review 2.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

3.  Formulation, Characterization, and Antitumor Properties of Trans- and Cis-Citral in the 4T1 Breast Cancer Xenograft Mouse Model.

Authors:  San Zeng; Arvinder Kapur; Manish S Patankar; May P Xiong
Journal:  Pharm Res       Date:  2015-02-12       Impact factor: 4.200

Review 4.  Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.

Authors:  Bo Xiao; Lijun Ma; Didier Merlin
Journal:  Expert Opin Drug Deliv       Date:  2016-07-06       Impact factor: 6.648

Review 5.  Delivery strategies and potential targets for siRNA in major cancer types.

Authors:  So Jin Lee; Min Ju Kim; Ick Chan Kwon; Thomas M Roberts
Journal:  Adv Drug Deliv Rev       Date:  2016-05-31       Impact factor: 15.470

6.  Modulation of oxidative stress and subsequent induction of apoptosis and endoplasmic reticulum stress allows citral to decrease cancer cell proliferation.

Authors:  Arvinder Kapur; Mildred Felder; Lucas Fass; Justanjot Kaur; Austin Czarnecki; Kavya Rathi; San Zeng; Kathryn Kalady Osowski; Colin Howell; May P Xiong; Rebecca J Whelan; Manish S Patankar
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

7.  Folate-mediated and pH-responsive chidamide-bound micelles encapsulating photosensitizers for tumor-targeting photodynamic therapy.

Authors:  Zhiqiang Ma; Pengwei Hu; Changyong Guo; Dan Wang; Xingjie Zhang; Min Chen; Qirong Wang; Miao Sun; Peiyu Zeng; Fengkun Lu; Linhong Sun; Lan She; Hongtao Zhang; Jianzhong Yao; Feng Yang
Journal:  Int J Nanomedicine       Date:  2019-07-22

8.  Safety Profile of Rapamycin Perfluorocarbon Nanoparticles for Preventing Cisplatin-Induced Kidney Injury.

Authors:  Qingyu Zhou; Justin Doherty; Antonina Akk; Luke E Springer; Ping Fan; Ivan Spasojevic; Ganesh V Halade; Huanghe Yang; Christine T N Pham; Samuel A Wickline; Hua Pan
Journal:  Nanomaterials (Basel)       Date:  2022-01-21       Impact factor: 5.076

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.